Nestlé S.A. (NESN.SW)
| Previous close | 93.90 |
| Open | 94.50 |
| Bid | 93.02 x 0 |
| Ask | 93.06 x 0 |
| Day's range | 93.02 - 94.56 |
| 52-week range | 89.52 - 108.50 |
| Volume | |
| Avg. volume | 4,046,831 |
| Market cap | 243.765B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 22.00 |
| EPS (TTM) | 4.23 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 3.00 (3.19%) |
| Ex-dividend date | 22 Apr 2024 |
| 1y target est | 106.39 |
The Telegraph‘Ozempic face’ supplements to combat side effects of rapid weight loss
Nestlé is to target “Ozempic face” by selling dietary supplements to counteract the effects of weight-loss drugs.
ReutersNestle, Coke take cautious approach to catering to Ozempic users
NEW YORK (Reuters) -Nestle's new food brand for people taking weight-loss drugs like Wegovy will note that the meals are high in protein, fiber and nutrients, but will not name the blockbuster medications, a company executive told Reuters. The world's largest food maker is keeping the names of the drugs off the packaging due to regulatory concerns, Tom Moe, Nestle USA's president of meals, said in a recent interview. Nestle will instead market its Vital Pursuit line of $5-and-under frozen meals on social media, he said.
BloombergKitKat Maker Sees Chocolate Demand Ebbing as Cocoa Costs Creep In
(Bloomberg) -- Consumers will probably cut back on chocolate as this year’s historic cocoa rally gradually trickles down to manufacturers and forces them to raise prices, a Nestle SA executive warned.Most Read from BloombergCar Dealerships Across US Halt Services After CyberattackWhat to Know About the Deadly Flesh-Eating Bacteria Spreading in JapanHedge Fund Talent Schools Are Looking for the Perfect TraderNvidia’s 591,078% Rally to Most Valuable Stock Came in Waves‘I Live in Hell’: Anti-Growth
